公开(公告)号：US11173467B2

公开(公告)日：2021-11-16

申请号：US16017535

申请日：2018-06-25

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A. Bourke, Jr.

IPC分类号： B01J19/12 ,  A23L3/26 ,  A61L2/00 ,  C02F1/30 ,  C02F1/72 ,  A23L5/30 ,  B01J19/08 ,  A61L2/08 ,  A61L2/10 ,  A61L2/16 ,  C08J3/28 ,  G21K5/00 ,  C02F1/32 ,  A61K41/00 ,  A61N5/06 ,  A61N5/10 ,  B01J23/50 ,  B01J23/52 ,  B01J31/02 ,  B01J31/22 ,  B01J35/00 ,  B01J37/00 ,  B01J37/02 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  A23L2/50 ,  A23L3/28 ,  C08J3/24 ,  C08J7/18 ,  G02B5/00 ,  A61M1/36 ,  C12H1/06 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00

摘要： A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

公开(公告)号：US20210035946A1

公开(公告)日：2021-02-04

申请号：US16995067

申请日：2020-08-17

申请人： Immunolight, LLC

发明人： Zakaryae FATHI ,  James CLAYTON ,  Harold WALDER ,  Frederic A. BOURKE, JR.

IPC分类号： H01L23/00 ,  C08K3/00 ,  B41J2/175 ,  C09J4/00 ,  A61B17/00 ,  A61L24/06 ,  B32B37/12 ,  B32B37/18 ,  B32B38/00 ,  C09J133/08 ,  C09K11/02 ,  C09K11/77 ,  H01L25/065 ,  H01L25/00 ,  B32B3/26 ,  B32B7/14 ,  B32B9/04 ,  C09J9/02 ,  C09J11/04 ,  C09J11/06 ,  H01L23/522

摘要： A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.

公开(公告)号：US10682624B2

公开(公告)日：2020-06-16

申请号：US16238443

申请日：2019-01-02

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. Bourke, Jr. ,  Tuan Vo-Dinh

IPC分类号： B01J19/12 ,  A23L3/26 ,  A61L2/00 ,  C02F1/30 ,  C02F1/72 ,  A23L5/30 ,  B01J19/08 ,  A61L2/08 ,  A61L2/10 ,  A61L2/16 ,  C08J3/28 ,  G21K5/00 ,  C02F1/32 ,  A61K41/00 ,  A61N5/06 ,  A61N5/10 ,  B01J23/50 ,  B01J23/52 ,  B01J31/02 ,  B01J31/22 ,  B01J35/00 ,  B01J37/00 ,  B01J37/02 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  A23L2/50 ,  A23L3/28 ,  C08J3/24 ,  C08J7/18 ,  G02B5/00 ,  A61M1/36 ,  C12H1/06 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00

摘要： A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

公开(公告)号：US10593642B2

公开(公告)日：2020-03-17

申请号：US16252060

申请日：2019-01-18

申请人： IMMUNOLIGHT, LLC.

发明人： Zakaryae Fathi ,  James Clayton ,  Harold Walder ,  Frederic A. Bourke, Jr.

IPC分类号： H01L23/29 ,  C09J9/02 ,  H01L23/00 ,  C09J11/02 ,  C09J163/00

摘要： A curable resin or adhesive composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and at least one energy converting material, preferably a phosphor, capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.

公开(公告)号：US20200009398A1

公开(公告)日：2020-01-09

申请号：US16554831

申请日：2019-08-29

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Mark OLDHAM ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Mark DEWHIRST ,  Neil L. SPECTOR ,  Paul YOON ,  Justus ADAMSON ,  David ALCORTA ,  Kim LYERLY ,  Leihua LIU ,  Takuya OSADA

IPC分类号： A61N5/06 ,  A61K31/352 ,  A61K41/00

摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：US20190308030A1

公开(公告)日：2019-10-10

申请号：US16295645

申请日：2019-03-07

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Frederic A. Bourke, JR. ,  Tuan Vo-Dinh

IPC分类号： A61N5/06 ,  A61K47/55 ,  A61K31/4427 ,  A61K41/00 ,  A61K31/7056

摘要： The present invention relates to methods for treating cell proliferation disorders comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder; and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes; a kit and a computer implemented system for performing the method; a pharmaceutical composition useful in the method; and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US10398777B2

公开(公告)日：2019-09-03

申请号：US15600921

申请日：2017-05-22

申请人： IMMUNOLIGHT, LLC

发明人： Frederic A. Bourke, Jr.

IPC分类号： A61K31/37 ,  A61K41/00 ,  A61K31/35 ,  A61K45/06 ,  A61K31/714 ,  A61K47/02 ,  A61F7/00 ,  A61H23/00 ,  A61K31/366 ,  A61N2/02 ,  A61N5/06 ,  A61N5/10

摘要： Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US10363541B2

公开(公告)日：2019-07-30

申请号：US15587601

申请日：2017-05-05

申请人： IMMUNOLIGHT, LLC.

发明人： Frederic A. Bourke, Jr.

IPC分类号： B01J19/12 ,  A23L3/26 ,  A61L2/00 ,  B01J19/08 ,  C02F1/30 ,  C02F1/72 ,  A61L2/08 ,  A61L2/10 ,  A61L2/16 ,  C08J3/28 ,  G21K5/00 ,  C02F1/32 ,  A61K41/00 ,  A61N5/06 ,  A61N5/10 ,  A23L5/30 ,  B01J23/50 ,  B01J23/52 ,  B01J31/02 ,  B01J31/22 ,  B01J35/00 ,  B01J37/00 ,  B01J37/02 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  A23L2/50 ,  A23L3/28 ,  C08J3/24 ,  C08J7/18 ,  G02B5/00 ,  A61M1/36 ,  C12H1/06 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00

摘要： A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

公开(公告)号：US20190184190A1

公开(公告)日：2019-06-20

申请号：US16322178

申请日：2017-08-01

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE ,  Zakaryae FATHI ,  Wayne BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Paul YOON

IPC分类号： A61N5/06 ,  A61N5/10 ,  A61P35/00 ,  A61K41/00

CPC分类号： A61N5/062 ,  A61K33/42 ,  A61K41/00 ,  A61K41/0057 ,  A61N5/10 ,  A61N2005/1098 ,  A61P35/00

摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

公开(公告)号：US20190134419A1

公开(公告)日：2019-05-09

申请号：US16096174

申请日：2017-04-25

申请人： Immunolight, LLC

发明人： Frederic A. BOURKE JR. ,  Harold WALDER ,  Zakaryae FATHI ,  Wayne F. BEYER, JR.

IPC分类号： A61N5/06 ,  A61N1/40 ,  A61N5/04 ,  A61M31/00 ,  A61K41/00

摘要： A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.